These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9496417)

  • 21. [Levofloxacin (Tavanic) in complex therapy of tuberculosis].
    Sokolova GB; Kunichan AD; Lazareva IaV
    Antibiot Khimioter; 2009; 54(1-2):31-7. PubMed ID: 19499715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe arthropathy with ofloxacin in two cases of MDR tuberculosis.
    Arora VK; Tumbanatham A
    Int J Tuberc Lung Dis; 1998 Nov; 2(11):941-3. PubMed ID: 9848618
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
    Sato A; Ogawa H; Iwata M; Ono T; Yasuda K; Nagayama M; Shirai T; Shirai M; Ida M; Suda T
    Drugs; 1995; 49 Suppl 2():428-9. PubMed ID: 8549388
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of additional oral ofloxacin administration in the treatment of multidrug-resistant tuberculosis.
    Sharma SK; Guleria R; Jain D; Chawla TC; Saha P; Mohan A; Jain NK
    Indian J Chest Dis Allied Sci; 1996; 38(2):73-9. PubMed ID: 8822640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sensitivity to levofloxacin of Mycobacterium tuberculosis strains with various phenotype isolated from patients with newly diagnosed and chronic tuberculosis].
    Vishnevskiĭ BI; Narvskaia OV; Mokrousov IV; Istomin EA; Otten TF
    Antibiot Khimioter; 2002; 47(6):31-3. PubMed ID: 12422646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levofloxacin alone efficiently treated a cutaneous mycobacterium fortuitum infection.
    Fujita N; Utani A; Matsumoto F; Matsushima H; Kakuta M; Hatamochi A; Shinkai H
    J Dermatol; 2002 Jul; 29(7):452-4. PubMed ID: 12184647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ofloxacin in multidrug resistant tuberculosis.
    Walwaikar PP; Morye VK; Gawde AS
    J Indian Med Assoc; 2003 Mar; 101(3):210-2. PubMed ID: 14603981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
    Jiang RH; Xu HB; Li L
    Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
    Jain A; Dixit P; Prasad R
    Tuberculosis (Edinb); 2012 Sep; 92(5):404-6. PubMed ID: 22789499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
    Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Javaid A; Ahmad N; Khan AH; Shaheen Z
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049176
    [No Abstract]   [Full Text] [Related]  

  • 35. gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand.
    Pitaksajjakul P; Worakhunpiset S; Chaiprasert A; Boonyasopun J; Ramasoota P
    Southeast Asian J Trop Med Public Health; 2011 Sep; 42(5):1163-7. PubMed ID: 22299442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
    Thee S; Garcia-Prats AJ; McIlleron HM; Wiesner L; Castel S; Norman J; Draper HR; van der Merwe PL; Hesseling AC; Schaaf HS
    Antimicrob Agents Chemother; 2014 May; 58(5):2948-51. PubMed ID: 24550337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
    Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of levofloxacine on cell elements of the lung tissue and on the growth of drug resistant Mycobacteria tuberculosis].
    Sokolova GB; Semenova OV; Bogadel'nikova IV; Kunichan AD
    Antibiot Khimioter; 2002; 47(6):12-7. PubMed ID: 12422642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.